Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant - PubMed (original) (raw)

Randomized Controlled Trial

doi: 10.1007/s00213-006-0358-7. Epub 2006 Mar 31.

Affiliations

• PMID: 16575552
• DOI: 10.1007/s00213-006-0358-7

Free article

Randomized Controlled Trial

Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant

Jordi Riba et al. Psychopharmacology (Berl). 2006 May.

Free article

Abstract

Rationale: Ayahuasca is a South American psychoactive plant tea which contains the serotonergic psychedelic N,N-dimethyltryptamine (DMT) and monoamine-oxidase inhibitors that render DMT orally active. Previous investigations with ayahuasca have highlighted a psychotropic effect profile characterized by enhanced introspective attention, with individuals reporting altered somatic perceptions and intense emotional modifications, frequently accompanied by visual imagery. Despite recent advances in the study of ayahuasca pharmacology, the neural correlates of acute ayahuasca intoxication remain largely unknown.

Objectives: To investigate the effects of ayahuasca administration on regional cerebral blood flow.

Methods: Fifteen male volunteers with prior experience in the use of psychedelics received a single oral dose of encapsulated freeze-dried ayahuasca equivalent to 1.0 mg DMT/kg body weight and a placebo in a randomized double-blind clinical trial. Regional cerebral blood flow was measured 100-110 min after drug administration by means of single photon emission tomography (SPECT).

Results: Ayahuasca administration led to significant activation of frontal and paralimbic brain regions. Increased blood perfusion was observed bilaterally in the anterior insula, with greater intensity in the right hemisphere, and in the anterior cingulate/frontomedial cortex of the right hemisphere, areas previously implicated in somatic awareness, subjective feeling states, and emotional arousal. Additional increases were observed in the left amygdala/parahippocampal gyrus, a structure also involved in emotional arousal.

Conclusions: The present results suggest that ayahuasca interacts with neural systems that are central to interoception and emotional processing and point to a modulatory role of serotonergic neurotransmission in these processes.

PubMed Disclaimer

Similar articles

• Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.
  Egger K, Aicher HD, Cumming P, Scheidegger M. Egger K, et al. Cell Mol Life Sci. 2024 Sep 10;81(1):395. doi: 10.1007/s00018-024-05353-6. Cell Mol Life Sci. 2024. PMID: 39254764 Free PMC article. Review.
• Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers.
  Riba J, Anderer P, Morte A, Urbano G, Jané F, Saletu B, Barbanoj MJ. Riba J, et al. Br J Clin Pharmacol. 2002 Jun;53(6):613-28. doi: 10.1046/j.1365-2125.2002.01609.x. Br J Clin Pharmacol. 2002. PMID: 12047486 Free PMC article. Clinical Trial.
• Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study.
  Sanches RF, de Lima Osório F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, de Araujo DB, Riba J, Crippa JA, Hallak JE. Sanches RF, et al. J Clin Psychopharmacol. 2016 Feb;36(1):77-81. doi: 10.1097/JCP.0000000000000436. J Clin Psychopharmacol. 2016. PMID: 26650973 Clinical Trial.
• Ayahuasca: Pharmacology, neuroscience and therapeutic potential.
  Domínguez-Clavé E, Soler J, Elices M, Pascual JC, Álvarez E, de la Fuente Revenga M, Friedlander P, Feilding A, Riba J. Domínguez-Clavé E, et al. Brain Res Bull. 2016 Sep;126(Pt 1):89-101. doi: 10.1016/j.brainresbull.2016.03.002. Epub 2016 Mar 11. Brain Res Bull. 2016. PMID: 26976063 Review.

Cited by

• Increased functional connectivity between brain regions involved in social cognition, emotion and affective-value in psychedelic states induced by N,N-Dimethyltryptamine (DMT).
  Soares C, Lima G, Pais ML, Teixeira M, Cabral C, Castelo-Branco M. Soares C, et al. Front Pharmacol. 2024 Oct 30;15:1454628. doi: 10.3389/fphar.2024.1454628. eCollection 2024. Front Pharmacol. 2024. PMID: 39539622 Free PMC article.
• Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.
  Egger K, Aicher HD, Cumming P, Scheidegger M. Egger K, et al. Cell Mol Life Sci. 2024 Sep 10;81(1):395. doi: 10.1007/s00018-024-05353-6. Cell Mol Life Sci. 2024. PMID: 39254764 Free PMC article. Review.
• Ayahuasca: A review of historical, pharmacological, and therapeutic aspects.
  Ruffell SGD, Crosland-Wood M, Palmer R, Netzband N, Tsang W, Weiss B, Gandy S, Cowley-Court T, Halman A, McHerron D, Jong A, Kennedy T, White E, Perkins D, Terhune DB, Sarris J. Ruffell SGD, et al. PCN Rep. 2023 Oct 2;2(4):e146. doi: 10.1002/pcn5.146. eCollection 2023 Dec. PCN Rep. 2023. PMID: 38868739 Free PMC article. Review.
• The possible place for psychedelics in pharmacotherapy of mental disorders.
  Wojtas A. Wojtas A. Pharmacol Rep. 2023 Dec;75(6):1313-1325. doi: 10.1007/s43440-023-00550-9. Epub 2023 Nov 7. Pharmacol Rep. 2023. PMID: 37934320 Free PMC article. Review.
• The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression.
  Buchborn T, Kettner HS, Kärtner L, Meinhardt MW. Buchborn T, et al. Front Neurosci. 2023 Oct 6;17:1232459. doi: 10.3389/fnins.2023.1232459. eCollection 2023. Front Neurosci. 2023. PMID: 37869510 Free PMC article. Review.

References

1. 1. Arch Gen Psychiatry. 1994 Feb;51(2):98-108 - PubMed
2. 1. Nat Neurosci. 2000 Oct;3(10 ):1049-56 - PubMed
3. 1. J Nerv Ment Dis. 1996 Feb;184(2):86-94 - PubMed
4. 1. Arch Gen Psychiatry. 1994 Feb;51(2):85-97 - PubMed
5. 1. Psychopharmacology (Berl). 2001 Feb;154(1):85-95 - PubMed

Publication types

MeSH terms

Substances